Sonde Health Appoints David Liu as CEO
24 Octubre 2019 - 01:00AM
Business Wire
Sonde Health Inc., a leading company developing a voice-based
technology platform to measure health when a person speaks, today
announced that David Liu has joined Sonde as chief executive
officer and a member of its board of directors. This appointment
follows the recently announced $16 million Series A financing
directed to advance Sonde’s capability across multiple health
conditions and device types as well as its commercialization
activities.
"Sonde Health’s vocal biomarker technology has the potential to
fundamentally transform the way we monitor and manage our health
and well-being. David’s wealth of experience at the intersection of
healthcare and technology along with his significant executive and
entrepreneurial experience position him perfectly to take Sonde to
the next stage of growth," said Edward Kliphuis, investment
director at M Ventures and board director at Sonde Health. “The
board and I are thrilled to have David lead and further strengthen
Sonde and its talented team.”
“A new wave of technology powered by voice is upon us, and its
application in healthcare has already begun to streamline
functional tasks such as researching providers, scheduling
appointments, and updating medical records,” said Mr. Liu. “Sonde
is at the forefront of taking voice technology beyond those tasks
to potentially improve people’s health outcomes by analyzing vocal
biomarkers combined with machine learning. I’m excited to join
Sonde and work with Jim Harper, our co-founder and COO, as we
continue to progress our platform as a fast, reliable, and
non-invasive health check built into widely used smartphone, voice
assisted, and telemedicine technologies.”
Sonde’s vocal biomarker platform has demonstrated the potential
to effectively detect disease using information obtained from an
individual’s voice on commonly-owned devices, such as smartphones
and smart speakers, and it has the potential to fundamentally
change the way mental and physical health is screened and
monitored.
Mr. Liu brings a wide range of leadership experiences across
consumer internet, education technology, and digital healthcare to
his role. He most recently served as president and chief operating
officer at Quartet, a growth stage enterprise healthcare technology
company that connects primary care physicians with mental health
providers to improve overall health outcomes for patients and
generate significant savings for payors. Before Quartet, Mr. Liu
was president and chief operating officer at Knewton, where - from
an early stage - he helped to build a leading global education
technology company that uses artificial intelligence to personalize
digital learning materials for K-20 students to improve individual
learning outcomes. Mr. Liu began his technology career with a
decade at AOL Inc., where he successfully led multiple product
areas and launched the original AOL.com portal as an internal
start-up.
Mr. Liu recently served as an entrepreneur-in-residence at Weill
Cornell Medicine (WCM), where he evaluated developing technologies
in therapeutics, diagnostics, devices and digital healthcare.
About Sonde Health Co-founded by PureTech Health (LSE:
PRTC), Sonde Health is developing a voice-based technology platform
to measure health when a person speaks. Sonde’s proprietary
technology works by sensing and analyzing subtle changes in the
voice to create a range of persistent brain, muscle, and
respiratory health measurements that provide a more complete
picture of health in just seconds. To date, Sonde has collected a
leading digital biobank containing millions of data points
comprising voice samples and health metadata from over 20,000
individuals as part of the ongoing validation of its platform.
Sonde has broad intellectual property coverage worldwide, currently
owning or having exclusive rights to eight patent applications and
three issued patents in five families of patent filings.
Forward Looking Statement This press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects,
developments, strategies and expectations regarding Mr. Liu’s role
at Sonde. The forward-looking statements are based on current
expectations and are subject to known and unknown risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from current expectations,
including, but not limited to, those risks and uncertainties
described in the risk factors included in the regulatory filings
for PureTech Health plc. These forward-looking statements are based
on assumptions regarding the present and future business strategies
of the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191023005779/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com U.S. media Tom Donovan +1 857 559
3397 tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024